EP0644946A1 - Particules vecteurs resistantes a l'inactivation par le serum humain - Google Patents

Particules vecteurs resistantes a l'inactivation par le serum humain

Info

Publication number
EP0644946A1
EP0644946A1 EP93913964A EP93913964A EP0644946A1 EP 0644946 A1 EP0644946 A1 EP 0644946A1 EP 93913964 A EP93913964 A EP 93913964A EP 93913964 A EP93913964 A EP 93913964A EP 0644946 A1 EP0644946 A1 EP 0644946A1
Authority
EP
European Patent Office
Prior art keywords
protein
amino acid
changed
vector particle
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93913964A
Other languages
German (de)
English (en)
Other versions
EP0644946A4 (fr
Inventor
W. French Anderson
James M. Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP0644946A1 publication Critical patent/EP0644946A1/fr
Publication of EP0644946A4 publication Critical patent/EP0644946A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • This invention relates to "injectable" vect particles. More particularly, this invention relates vector particles, such as retroviral vector particle wherein such vector particles are resistant to inactivati by human serum.
  • Vector particles are useful agents for introduci gene(s) or DNA (RNA) into a cell, such as a eukaryotic cel
  • the gene(s) is controlled by an appropriate promote
  • vectors which may be employed to generate vect particles include prokaryotic vectors, such as bacteri vectors; eukaryotic vectors, including fungal vectors su as yeast vectors; and viral vectors such as DNA vir vectors, RNA virus vectors, and retroviral vector Retroviruses which have been employed for generating vect particles for introducing genes or DNA (RNA) into a ce include Moloney Murine Leukemia Virus, Spleen Necros Virus, Rous Sarcoma Virus and Harvey Sarcoma Virus.
  • T term "introducing” as used herein encompasses a variety methods of transfering genes or DNA (RNA) into a cell. Su methods include transformation, transduction, transfectio and infection.
  • Vector particles have been used for introducing D (RNA) into cells for gene therapy purposes.
  • RNA D
  • Such a procedure involves obtaining cells from a patient a using a vector particle to introduce desired DNA (RNA) i the cells and then providing the patient with the engineer cells for a therapeutic purpose.
  • RNA DNA
  • Such alternative procedure would involve genetically engineeri cells jLn vivo.
  • a vector particle whic includes the desired DNA (RNA) would be administered to patient for .in vivo delivery to the cells of a patient.
  • an object of the present invention t provide gene therapy by introduction of a vector particle such as, for example, a retroviral vector particle, into patient, wherein the vector particle is resistant t inactivation by human serum.
  • a vector particle such as, for example, a retroviral vector particle
  • the vecto particle is a viral vector particle, and more preferably th viral vector particle is a retroviral vector particle.
  • retroviruses include a protei known as pl5E, and Applicants have found that retroviruse are susceptible to inactivation by human serum as a resul of the action of complement protein(s) present in serum o the pl5E protein portion of the retroviru ⁇ . Applicants hav further found that such retroviruses can be made resistan to inactivation by human serum by mutating such pl5 protein.
  • a retrovira vector wherein a portion of the DNA encoding pl5E protei (shown in the accompanying sequence listing), has bee mutated to render the vector particle resistant t inactivation by human serum.
  • the terms "mutated” an “mutation” as used herein mean that the DNA encoding pl5 protein has been changed such that at least one but not al of the amino acids of pl5E protein have been changed (suc changes can include point mutations, deletions, and/o insertions) .
  • pl5E protein is a viral protein having 196 amino aci residues.
  • viruses can contain both the pl5E and pl2 proteins.
  • pl5E protein is anchored in the viral membran such that amino acid residues 1 to 134 are present on th outside of the virus.
  • the pl5E protein includes tw regions, amino acid residues 39 to 61 (sometimes hereinafte referred to as region 1), and amino acid residues 101 to 12 (sometimes hereinafter referred to as region 2), whic Applicants believe have an external location in th three-dimensional structure of the pl5E protein; i.e., suc regions are directly exposed to human serum.
  • Region 2 is highly conserved region in many retroviruses, even thoug the amino acid sequences of this region are not identical i all retroviruses.
  • Such regions are complement bindin regions. Examples of complement proteins which may bind t the complement binding regions are CIS and C1Q, which bin to regions 1 and 2.
  • complement protein bind to both region 1 and region 2.
  • at least one portion of DNA encoding complement binding region of pl5E protein has been mutated Such a mutation results in a change of at least one amin acid residue of a complement binding region of pl5E protein
  • the change in at least one amino acid residue of complement binding region of pl5E protein prevents bindin of a complement protein to the complement binding region thereby preventing complement inactivation of th retrovirus.
  • at least one amino aci residue in both complement binding regions of pl5E prote is changed, whereas in another embodiment, at least o amino acid residue in one of the complement binding regio is changed.
  • the at least one portion of D encoding pl5E protein is mutated such that at least o positively charged amino acid residue or negatively charg amino acid residue is changed to an amino acid resid having the opposite charge.
  • the positively charged amino acids are His, Lys, a Arg.
  • the negatively charged amino acids are Asp and Glu.
  • the at least one portion of D encoding pl5E protein is mutated such that at least o positively charged amino acid or negatively charged ami acid is changed to a noncharged amino acid.
  • the at least one portion of D encoding a complement binding region of pl5E protein whi is mutated, encodes one or more of amino acid residues 1 to 123 of pl5E protein.
  • the at least o portion of DNA encoding pl5E protein is mutated such th amino acid residue 122 is changed.
  • the at least one portion of D encoding pl5E protein is mutated such that at least one amino acid residues 117 and 122 are changed.
  • Preferabl amino acid residue 117 is changed from Arg to Glu
  • ami acid residue 122 is changed from Glu to Gin.
  • the at least one portion of D encoding pl5E protein ⁇ Yts mutated such that amino ac residues 104, 105, 109, and 111 are changed.
  • Preferabl amino acid residue 104 is changed from Arg to His
  • ami acid residue 105 is changed from Asp to Asn
  • amino ac residue 109 is changed from Lys to Gin
  • amino ac residue ill is changed from Arg to Gin.
  • the at least one portion of D encoding pl5E protein is mutated such that amino ac residues 104, 105, 109, 111, 117, and 122 are change
  • the at least one portion of DNA is mutated su that amino acid residue 104 is changed from Arg to Hi amino acid residue 105 is changed from Asp to Asn, ami acid residue 109 is changed from Lys to Gin, amino ac residue 111 is changed from Arg to Gin, amino acid resid 117 is changed from Arg to Glu, and amino acid residue 1 is changed from Glu to Gin.
  • the mutation DNA encoding pl5E protein may be effected by deleting portion of the pl5E gene, and replacing the deleted porti of the pl5E gene, with fragment(s) or portion(s) of a ge encoding another viral protein.
  • o portion of DNA encoding the pl5E protein is replaced with fragment of the gene encoding the p21 protein, which is HTLV-I transmembrane protein.
  • HTLV-I virus has been fou to be resistant to binding by complement proteins and th HTLV-I is resistant to inactivation by human serum (Hoshin et al., Nature, Vol. 310, pgs. 324-325 (1984)).
  • a retroviral vect particle wherein a portion of the pl5E protein has be deleted and replaced with a portion of another vir protein, such as a portion of the p21 protein.
  • p21 protein (as shown in the accompanying sequenc listing) is a protein having 176 amino acid residues, an which, in relation to pl5E, has significant amino aci sequence homology.
  • at least amino aci residues 39 to 61, and 101 to 123 are deleted from pl5 protein, and replaced with amino acid residues 34 to 56 an 96 to 118 of p21 protein.
  • at leas amino acid residues 39 to 123 of pl5E protein are delete and replaced with amino acid residues 34 to 118 of p2 protein.
  • amino acid residues 39 to 69 o pl5E protein are deleted and replaced with amino aci residues 34 to 64 of p21 protein, and amino acid residues 9 to 123 of pl5E protein are deleted and replaced with amin acid residues 91 to 118 of p21 protein.
  • Vector particles thus generated, and which ar resistant to inactivation by human serum, may be engineere such that the vector particles may, when introduced into patient, travel directly to a target cell or tissue.
  • the vector particle furthe includes a protein which contains a receptor binding regio that binds to a receptor of a human target cell, such as for example, but not limited to, the amphotropic cel receptor.
  • retroviral vectors hereinabove described may b constructed by genetic engineering techniques known to thos skilled in the art.
  • the retroviral vector may be of th LN series of vectors, as described in Bender, et al. J.Virol., Vol. 61, pgs. 1639-1649 (1987) and Miller, et al. Biotechniques, Vol. 7, pgs. 980-990 (1989).
  • the retroviral vector includes multiple restriction enzyme site, or multiple cloning site
  • the multiple cloning site includes at least four cloning, o restriction enzyme sites, wherein at least two of the site have an average frequency of appearance in eukaryotic gene of less than once in 10,000 base pairs; i.e., th restriction product has an average size of at least 10,00 base pairs.
  • restriction sites also sometime hereinafter referred to as "rare" sites, which have a average frequency of appearance in eukaryotic genes of les than once in 10,000 base pairs, contain a CG doublet withi their recognition sequence, such doublet appearin particularly infrequently in the mammalian genome.
  • Anothe measure of rarity or scarcity of a restriction enzyme sit in mammals is its representation in mammalian viruses, suc as SV40.
  • an enzyme whose recognition sequenc is absent in SV40 may be a candidate for being a "rare mammalian cutter.
  • restriction enzyme sites having an averag frequency of appearance in eukaryotic genes of less tha once in 10,000 base pairs include, but are not limited t the NotI, SnaBI, Sail, Xhol, Clal, Sad, EagI, and Sma sites.
  • Preferred cloning sites are selected from the grou consisting of NotI, SnaBI, Sail, and Xhol.
  • the multiple cloning site has a length n greater than about 70 base pairs, and preferably no greate than about 60 base pairs.
  • the multipl restriction enzyme site, or multiple cloning site is locate between the 5'LTR and 3' TR of the retroviral vector.
  • Th 5' end of the multiple cloning site is no greater than abou 895 base pairs from the 3' end of the 5' LTR, and preferabl at least about 375 base pairs from the 3' end of the 5' LTR
  • the 3* end of the multiple cloning site is no greater tha about 40 base pairs fro... the 5 1 end of the 3' LTR, an preferably at least 11 base pairs from the 5' end of the 3 LTR.
  • Such vectors may be engineered from existing retrovira vectors through genetic engineering techniques known in th art such that the resulting retroviral vector includes a least four cloning sites wherein at least two of the clonin sites are selected from the group consisting of the NotI SnaBI, Sail, and Xhol cloning sites.
  • the retroviral vector includes each of the NotI SnaBI, Sail, and Xhol cloning sites.
  • Such a retroviral vector may serve as part of a clonin system for the transfer of genes to eukaryotic cells.
  • a cloning system for the manipulatio of genes in a retroviral vector which includes a retrovira vector including a multiple cloning site of the typ hereinabove described, and a shuttle cloning vector whic includes at least two cloning sites which are compatibl with at least two cloning sites selected from the grou consisting of NotI, SnaBI, Sail, and Xhol located on th retroviral vector.
  • the shuttle cloning vector also include at least one desired gene which is capable of bein transferred from said shuttle cloning vector to sai retroviral vector.
  • the shuttle cloning vector may be constructed from basic "backbone" vector or fragment to which are ligated on or more linkers which include cloning or restriction enzym recognition sites. Included in the cloning sites are th compatible, or complementary cloning sites hereinabov described. Genes and/or promoters having ends correspondin to the restriction sites of the shuttle vector may b ligated into the shuttle vector through techniques known i the art.
  • the shuttle cloning vector can be employed to amplif DNA sequences in prokaryotic systems.
  • the shuttle cloni vector may be prepared from plasmids generally used i prokaryotic systems and in particular in bacteria. Thus for example, the shuttle cloning vector may be derived fro plasmids such as pBR322; pUCl ⁇ ; etc.
  • the DNA encoding pl5E protein whic has been mutated to render a vector particle resistant t inactivation by human serum may be contained in a expression vehicle other than a retroviral vector.
  • Suc expression vehicles include, for example, viral vecto other than retroviral vectors, or any expression plasmi which is capable of being transferred into a cell line whic is capable of producing vector particles which include t mutated pl5E protein.
  • Such vectors or expression vehicles which contain D encoding a mutated env protein such as the mutated pl5 protein hereinabove described, are transferred into pre-packaging cell line to generate vector particles.
  • the pre-packaging cell line contains the gag an pol proteins of the virus, plus a retroviral vector lackin the structural gag, pol, and env proteins.
  • An example o such a pre-packaging cell line is the GPL pre-packaging cel line which consists of an NIH 3T3 mouse fibroblast cell li which contains an expression plasmid for MoMuLV gag-po protein as well as the retroviral vector LNL6 (Miller, al., Biotechniques, Vol. 7, pgs. 980-990 (1989)). It is be understood, however, that the scope of the prese invention is not to be limited to any particul pre-packaging cell line.
  • the pre-packaging cell line Upon transfection of the pre-packaging cell line wi an expression vehicle containing DNA encoding a mutated e protein, the pre-packaging cell line will generate vector particles. The vector particles are then tested for complement resistance. The vector particles which are shown to be complement resistant (i.e., not inactivated by human serum), therefore, contain complement resistant envelope proteins encoded by a specific envelope expression vehicle.
  • Such an expression vehicle can then be used, by techniques known to those skilled in the art, to produce a packaging cell line which contains an expression vehicle encoding the retroviral gag and pol proteins, and an expression vehicle containing a gene encoding the mutated env protein (such as, for example, an expression vehicle or expression plasmid containing a mutated pl5E protein such as hereinabove described), whereby such packaging cell line may be employed to generate vector particles which are resistant to inactivation by human serum.
  • a retroviral vector which lacks the structural gag, pol, and env genes, but includes a desired gene of interest, may be transferred into such a packaging cell line.
  • the packaging cell line may generate vector particles which contain a desired gene(s) of interest, and which are resistant to inactivation by human serum.
  • the vector particles generated from the packaging cell line will not be inactivated when contacted with human serum; and in addition, such vector particles, when engineered with protein containing a receptor binding region for a human receptor, are targetable, whereby the receptor binding region for a human receptor enables the vector particles to bind to a target cell.
  • retroviral vector particles may be directly introduced into the body (e.g., by intravenous, intramuscular, or subcutaneous injection, intranasally, orally, rectally or vaginally), and travel to a desired target cell.
  • Such vector particles therefore, are useful for the introduction of desire heterologous genes into target cells in vivo as a gen therapy procedure.
  • the vectors of the present inventio further include at least one heterologous gene
  • Heterologous or foreign genes which may be placed into th vector or vector particles include, but are not limited to genes which encode cytokines or cellular growth factors such as lymphokines, which are growth factors fo lymphocytes.
  • Other examples of foreign genes include, bu are not limited to, genes encoding Factor VIII, Factor IX tumor necrosis factors (TNF's), ADA, ApoE, ApoC, and Protei C.
  • the vectors of the present invention include one o more promoters.
  • Suitable promoters which may be employe include, but are not limited to, the retroviral LTR; th SV40 promoter; and the human cytomegalovirus (CMV) promote described in Miller, et al., Biotechniques, Vol. 7, No. 9 pgs. 980-990 (1989), or any other promoter (eg., cellula promoters such as eukaryotic cellular promoters including but not limited to, the histone, pol III, and ⁇ -acti promoters).
  • Other viral promoters which may be employe include, but are not limited to adenovirus promoters, T promoters, and B19 parvovirus promoters. The selection of suitable promoter will be apparent to those skilled in th art from the teachings contained herein.
  • the vectors of the present invention may contai regulatory elements, where necessary, to ensure tissu specific expression of the desired heterologous gene(s) and/or to regulate expression of the heterologous gene(s) i response to cellular or metabolic signals.
  • retroviral vector particles other viral vector particle (such as, for example, adenovirus and adeno-associated vir particles), or synthetic particles may be construct wherein a region of the envelope protein in the vect particle may be mutated such that the vector partic becomes resistant to inactivation by human serum, there making such vector particles suitable for in vi administration.
  • viral vector particle such as, for example, adenovirus and adeno-associated vir particles
  • synthetic particles may be construct wherein a region of the envelope protein in the vect particle may be mutated such that the vector partic becomes resistant to inactivation by human serum, there making such vector particles suitable for in vi administration.
  • Plasmid pCE2 was constructed from pBR322 such that t resulting plasmid pCE2 includes genes encoding the envelo proteins gp70 and pl5E.
  • pBR322 ( Figure 1) was cut wi EcoRI and filled in to destroy the EcoRI site to gi pBR322Z Rl.
  • pBR3224Rl was then cut with Ndel and filled to destroy the Ndel site to give pBR322
  • a R pBR322_4 R N was digested with Hindi11 and EcoRV, a cloned into the Hindlll/EcoRV fragment was a Hindlll/Fs cassette containing the gp70 and pl5E genes under t control of a cytomegalovirus (CMV) intermediate ear promoter with a polyA (adenine) tail from SV40 ( Figure from plasmid pCEE. ( Figure 3).
  • CMV cytomegalovirus
  • the Hindlll/Fspl casset obtained from plasmid pCEE contains a CMV intermediate ear promoter in which the Ball/Sac11 (bp 21 to bp 766) w converted to an Hindlll/Sall fragment by linker additio the ecotropic envelope Bglll/Nhel fragment (bp 5408 to 7847 of MoMuLV, encoding gp70 and pl5E) was filled and Eco linkers were added; and the SV40 poly A signal from Bell BamHI (bp 2770 to bp 2533) was cloned into a BamHI si (thereby destroying the Bell site). A Bglll site was add at the 3 1 end of the gp70 gene. (This addition does n alter any amino acids).
  • the resulting plasmid is pCE ( Figure 4. )
  • pUC-E2 sub-loning i carried out in a different plasmid called pUC-E2 ( Figure 6.)
  • This plasmid is pUC18 ( Figure 5) with the PvuI fragment removed and replaced with EcoRI linkers.
  • Int the EcoRI site was cloned the MoMuLV ecotropic envelope gen (i.e., the gp70 and pl5E genes from pCE2) from the Bgll site (5408) to the Nhel site (7847), which have been blunte and had EcoRI linkers added.
  • the resulting pUC-E2 plasmi ( Figure 6) therefore has unique Bglll, Spel, Clal, and PvuI sites in and around the pl5E gene.
  • PCR primers are then synthesized to encode th following mrtations in the pl5E protein (using pCE2 as template):
  • Amino acid residue 117 is changed from Arg to Glu and amino acid residue 122 is changed from Glu to Gin;
  • Amino acid residue 104 is changed from Arg to His amino acid residue 105 is changed from Asp to Asn, amin acid residue 109 is changed from Lys to Gin, and amino aci residue 111 is changed from Arg to Gin;
  • Amino acid residue 104 is changed from Arg to His amino acid residue 105 is changed from Asp to Asn, amin acid residue 109 is changed from Lys to Gin, amino aci residue 111 is hanged from Arg to Gin, amino acid residu 117 is changed from Arg to Glu, and amino acid residue 12 is changed from Glu to Gin.
  • Each PCR product is digested with Spel and PvuII, a cloned into pUC-E2 at the unique Spel and PvuII sites. T resulting plasmids are then sequenced to confirm the poi mutations. DNA fragments bearing these mutations are the subcloned into the expression plasmid pCE2.
  • pCE2 i digested with EcoRI and the envelope DNA fragment is remove and replaced with the EcoRI envelope fragment from th pUC-E2 plasmids.
  • the resulting pCE2 plasmids are the checked for orientation of the EcoRI fragment and sequence again (only at the cloning site junctions and at the region bearing the point mutations) to confirm the presence of th newly created mutated pl5E genes.
  • the resulting expressio plasmids are identified as follows: pCR68 - includes mutations in which amino acid residu 117 is changed from Arg to Glu, and amino acid residu 122 is changed from Glu to Gin; pCR69 - includes mutations in which amino acid residu 104 is changed from Arg to His, amino acid residue 10 is changed from Asp to Asn, amino acid residue 109 i changed from Lys to Gin, and amino acid residue 111 i changed from Arg to Gin; and pCR70 - includes mutations in which amino acid residu 104 is changed from Arg to His, amino acid residue 10 is changed from Asp to Asn, amino acid residue 109 i changed from Lys to Gin,
  • Plasmids pCR68, pCR69, and pCR70 are transfecte separately into the GPL pre-packaging cell line.
  • the GP pre-packaging cell line consists of an NIH 3T3 mous fibroblast cell line which contains an expression plasmi for MoMuLV gag-pol protein as well as the retroviral vecto LNL6 (Miller, et al., 1989).
  • the GPL packaging cell line produces vecto particles. Transiently expressed vector particles are collecte with cell supernatant at 48-72 hrs. post-transfection.
  • the vector particles generated as hereinabove describ may then be assayed for vector titer by techniques known those skilled in the art.
  • the vector particles may also collected in viral supernatant and concentrated, i necessary, according to procedures known to those skilled i the art in order to employ such vector particles in assa or in therapeutic procedures.
  • Advantages of the present invention include the abili to introduce vector particles directly into a human patie whereby the vector particle is not lysed or inactivated human serum upon such introduction.
  • the vect particles of the present invention enable one to deliv desired genes to a patient in vivo.
  • Such vector particl may also be engineered such that they are "targetable", well as injectable, thereby enabling the vector particles travel directly to a target cell or tissue without bei lysed or inactivated by human serum.
  • ADDRESSEE Carella, Byrne, Bain,
  • Glu Lys Ser lie Ser Asn Leu Glu Lys Ser
  • Lys Asp Arg lie Ser Val Val Gin Ala Leu

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Particule vecteur rétrovirale résistante à l'inactivation par le sérum humain. Les particules vecteurs comprennent de préférence la protéine p15E, au moins une partie de l'ADN codant la protéine p15E étant mutée de sorte que la particule vecteur devienne résistante à l'inactivation par le sérum humain. Les particules vecteurs peuvent comprendre en outre une protéine contenant une région de liaison de récepteur qui se lie au récepteur d'une cellule cible humaine, ce qui permet l'introduction directe in vivo de gènes hétérologues requis, de sorte que la particule vecteur comprenant le gène hétérologue se dirige directement vers une cellule ou des tissus cibles.
EP93913964A 1992-06-10 1993-05-14 Particules vecteurs resistantes a l'inactivation par le serum humain. Withdrawn EP0644946A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US896603 1978-04-14
US89660392A 1992-06-10 1992-06-10
PCT/US1993/004706 WO1993025698A1 (fr) 1992-06-10 1993-05-14 Particules vecteurs resistantes a l'inactivation par le serum humain

Publications (2)

Publication Number Publication Date
EP0644946A1 true EP0644946A1 (fr) 1995-03-29
EP0644946A4 EP0644946A4 (fr) 1997-03-12

Family

ID=25406489

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93913964A Withdrawn EP0644946A4 (fr) 1992-06-10 1993-05-14 Particules vecteurs resistantes a l'inactivation par le serum humain.

Country Status (4)

Country Link
EP (1) EP0644946A4 (fr)
JP (1) JPH09507741A (fr)
CA (1) CA2137361A1 (fr)
WO (1) WO1993025698A1 (fr)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003834A1 (fr) * 1993-07-28 1995-02-09 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services PRE-LIAISON DE PARTICULES DE VECTEURS RETROVIRAUX DE COMPOSANTS DE COMPLEMENT DESTINEE A PERMETTRE UNE THERAPIE GENIQUE HUMAINE $i(IN VIVO)
JPH10507905A (ja) * 1994-08-17 1998-08-04 ジェネティック セラピー インコーポレイテッド ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
GB9517263D0 (en) * 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
EP0915975A2 (fr) * 1996-07-03 1999-05-19 Chiron Corporation Procedes d'administration d'excipients d'apport de genes recombines dans le traitement de l'hemophilie
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1999006576A1 (fr) 1997-08-04 1999-02-11 Calydon, Inc. Sequence stimulatrice de la kallicreine glandulaire chez l'homme, vecteurs comprenant cette sequence et procedes d'utilisation de ces derniers
EP2386629A1 (fr) 1997-10-14 2011-11-16 Darwin Molecular Corporation Mutants de kinase de thymidine et protéines de fusion ayant de la kinase de thymidine et activités de kinase de guanylate
CA2308606A1 (fr) 1997-11-06 1999-05-20 Chiron S.P.A. Antigenes de neisseria
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
EP1121437B1 (fr) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE338120T2 (de) 1998-11-27 2006-09-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20030008284A1 (en) 2000-06-15 2003-01-09 Giulia Kennedy Polynucleotides related to colon cancer
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
EP1854476A3 (fr) 2000-02-09 2008-05-07 Bas Medical, Inc. Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction
EP1261638A2 (fr) 2000-03-08 2002-12-04 Chiron Corporation Gene humain fgf-23 et produits d'expression associes
EP1950297A2 (fr) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
EP1415005B1 (fr) 2000-12-07 2012-11-21 Novartis Vaccines and Diagnostics, Inc. Retrovirus endogenes regules positivement dans le cancer de la prostate
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081639A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 et ses utilisations diagnostiques et therapeutiques
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002090600A2 (fr) 2001-05-08 2002-11-14 Darwin Molecular Corporation Methode de regulation de la fonction immune chez les primates a l'aide de la proteine foxp3
EP2292772A1 (fr) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
WO2003060143A2 (fr) 2001-10-26 2003-07-24 Id Biomedical Corporation Of Washington Systeme d'expression de proteine efficace
AU2002359446B2 (en) 2001-11-09 2008-12-04 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
EP1472375B1 (fr) 2002-01-08 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Produits geniques a expression differenciee dans des cellules cancereuses du sein et methodes d'utilisation associees
BR0308441A (pt) 2002-03-15 2005-01-18 Wyeth Corp Proteìna variante de p4 de haemophilus influenzae não tipificável, composição imunogênica, molécula de nucleotìdeo isolada, célula hospedeira, e, métodos para induzir uma resposta imune em um ser humano contra h. influenzae não tipificável, e para produzir uma proteìna variante de p4
US20040023267A1 (en) 2002-03-21 2004-02-05 Morris David W. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004058184A2 (fr) 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004074321A2 (fr) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Nouveaux cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP1594441B1 (fr) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Methode de traitement de la douleur consistant a administrer un antagoniste du facteur de croissance neuronale ainsi que des medicaments anti-inflammatoires non steroidiens (nsaid) et composition les contenant
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1619951B1 (fr) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methodes et compositions destinees a traiter des troubles
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
CA2551097A1 (fr) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Anticorps anti-trkc agonistes et procedes d'utilisation
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
EP1789593B1 (fr) 2004-07-09 2017-03-15 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Formes solubles de glycoproteine g des virus hendra
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
EP1907425B1 (fr) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anticorps anti-cd26 et methodes d'utilisation de ces derniers
EP1912675B1 (fr) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
ES2664854T3 (es) 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
CA2637707A1 (fr) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Procedes de traitement de l'obesite par administration d'un antagoniste trkb
EP1993558B1 (fr) 2006-02-27 2014-07-30 The Regents of The University of California Composés oxystérols et hedgehog voie
SG10201604649SA (en) 2006-06-07 2016-07-28 Bioalliance Cv Antibodies Recognizing A Carbohydrate Containing Epitope On CD-43 And Cea Expressed On Cancer Cells And Methods Using Same
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
EP2155777A2 (fr) 2007-04-10 2010-02-24 The Administrators of the Tulane Educational Fund Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101499278B1 (ko) 2007-12-17 2015-03-06 화이자 리미티드 간질성 방광염의 치료
JP5568478B2 (ja) 2007-12-18 2014-08-06 バイオアライアンス セー．フェー． 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
US10000568B2 (en) 2008-04-10 2018-06-19 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR in cancer
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010080985A1 (fr) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induire la différenciation du tissu adipeux brun
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
WO2010118243A2 (fr) 2009-04-08 2010-10-14 Genentech, Inc. Utilisation d'antagonistes de il-27 pour traiter le lupus
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
EP2448960A1 (fr) * 2009-06-30 2012-05-09 Abbott Laboratories Marqueurs d'infection du virus xmrv et leurs utilisations
MX2012000734A (es) 2009-07-16 2012-01-27 Novartis Ag Inmunogenos destoxificados de escherichia coli.
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20130040853A1 (en) 2010-01-21 2013-02-14 Dana-Farber Cancer Institute Inc. Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
CA2832307A1 (fr) 2011-04-08 2012-10-18 Immune Design Corp. Compositions immunogenes et leurs procedes d'utilisation pour induire des reponses immunitaires humorales et cellulaires
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (fr) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions et procédés pour traiter le cancer
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
WO2013055911A1 (fr) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
IN2014CN04652A (fr) 2011-12-22 2015-09-18 Rinat Neuroscience Corp
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CA2872751A1 (fr) 2012-05-07 2013-11-14 The Regents Of The University Of California Oxy133, un analogue de l'oxysterol, induisant l'osteo-genese et la signalisation hedgehog et inhibant l'adipogenese
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CA2890483A1 (fr) 2012-11-09 2014-05-15 Robert ARCH Anticorps specifiques du facteur de croissance b derive des plaquettes, leurs compositions et leurs utilisations
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
CA2906624A1 (fr) 2013-03-15 2014-09-25 Dyax Corp. Anticorps anti-kallicreine plasmatique
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
CN105263500A (zh) 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10711275B2 (en) 2013-07-12 2020-07-14 Zhen Huang Methods and compositions for interference with DNA polymerase and DNA synthesis
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102048718B1 (ko) 2013-08-02 2019-11-26 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
BR112016009797A2 (pt) 2013-11-13 2017-12-05 Bristol Myers Squibb Co anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
WO2015109212A1 (fr) 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
WO2015164743A2 (fr) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR102246800B1 (ko) 2014-05-13 2021-04-30 바이오아트라, 인코퍼레이티드 조건부 활성 생체 단백질
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2913865T3 (es) 2014-08-28 2022-06-06 Bioatla Inc Receptores de antígeno quimérico condicionalmente activos para células T modificadas
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
EP3189152A4 (fr) 2014-09-03 2018-04-04 BioAtla LLC Découverte et production de protéines biologiques conditionnellement actives dans les mêmes cellules hôtes eucaryotes de production
SG10201902168PA (en) 2014-09-09 2019-04-29 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
WO2016057367A1 (fr) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
EP3204119B1 (fr) 2014-10-09 2021-06-09 Dana-Farber Cancer Institute, Inc. Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3265825A4 (fr) 2015-03-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
PL3283106T3 (pl) 2015-04-13 2022-05-02 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
KR20180096567A (ko) 2015-07-21 2018-08-29 다이액스 코포레이션 Xiia 인자의 단일클론 항체 저해제
WO2017015334A1 (fr) 2015-07-21 2017-01-26 Saint Louis University Compositions et méthodes pour diagnostiquer et traiter l'infertilité associée à l'endométriose
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
PE20180556A1 (es) 2015-08-19 2018-04-02 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
CA3001859A1 (fr) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions et methodes d'inhibition d'antigenes specifiques a une lignee
WO2017066561A2 (fr) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
EP3365369A1 (fr) 2015-10-23 2018-08-29 Pfizer Inc Anticorps anti-il-2, compositions les contenant et leurs utilisations
WO2017075037A1 (fr) 2015-10-27 2017-05-04 Scholar Rock, Inc. Facteurs de croissance amorcés et leurs utilisations
WO2017075329A2 (fr) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Procédés pour identifier, évaluer, prévenir et traiter des troubles métaboliques au moyen de pm20d1 et d'acides aminés n-lipidés
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017125831A1 (fr) 2016-01-21 2017-07-27 Pfizer Inc. Anticorps mono et bispécifiques contre le variant iii du récepteur du facteur de croissance épidermique et contre le cd3, et leurs utilisations
AU2017238054B2 (en) 2016-03-21 2023-10-19 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
HRP20221298T1 (hr) 2016-05-13 2022-12-23 Bioatla, Inc. Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
KR20220165789A (ko) 2016-06-01 2022-12-15 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
US11136409B2 (en) 2016-09-20 2021-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
WO2018080573A1 (fr) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Plate-forme de criblage régulatrice globale crispr/cas
US20190345501A1 (en) 2017-02-07 2019-11-14 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
JP2020510435A (ja) 2017-03-03 2020-04-09 ライナット ニューロサイエンス コーポレイション 抗ｇｉｔｒ抗体およびその使用方法
EP3596206A1 (fr) 2017-03-16 2020-01-22 Pfizer Inc Prototrophie à la tyrosine
EP3610010A4 (fr) 2017-04-14 2021-02-24 Kodiak Sciences Inc. Anticorps antagonistes du facteur d du complément et leurs conjugués
US11421040B2 (en) 2017-06-02 2022-08-23 Pfizer Inc. Antibodies specific for FLT3 and their uses
WO2018226685A2 (fr) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Procédés de sensibilisation de cellules cancéreuses à une destruction médiée par des lymphocytes t par modulation de voies moléculaires
KR102396784B1 (ko) 2017-06-13 2022-05-13 보스턴진 코포레이션 분자 기능적 프로파일을 생성하고, 시각화하고, 분류하는 시스템 및 방법
WO2019014418A1 (fr) 2017-07-13 2019-01-17 Massachusetts Institute Of Technology Ciblage du complexe hdac2-sp3 pour améliorer la fonction synaptique
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
WO2019056015A2 (fr) 2017-09-18 2019-03-21 Children's Hospital Medical Center Isolateur fort et ses utilisations dans l'administration de gène
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
KR20200115596A (ko) 2018-02-01 2020-10-07 화이자 인코포레이티드 Cd70에 특이적인 항체 및 이의 용도
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN113286634A (zh) 2018-05-23 2021-08-20 辉瑞公司 对gucy2c特异性的抗体及其用途
SG11202010580TA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for cd3 and uses thereof
CA3104862A1 (fr) 2018-07-03 2020-01-09 Sotio, LLC Recepteurs chimeriques en association avec des molecules de metabolisme trans ameliorant l'importation de glucose et leurs utilisations therapeutiques
US12077785B2 (en) 2018-08-14 2024-09-03 Sotio Biotech Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
EP3844187A1 (fr) 2018-08-28 2021-07-07 Vor Biopharma, Inc. Cellules souches hématopoïétiques génétiquement modifiées et utilisations associées
EP3962529A4 (fr) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3152623A1 (fr) 2019-10-11 2021-04-15 Richard D. Cummings Anticorps anti-tn et leurs utilisations
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (fr) 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
WO2021224850A1 (fr) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Peptides masques et anticorps anti-ptk7 masqués les comprenant
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
WO2022023972A1 (fr) 2020-07-30 2022-02-03 Pfizer Inc. Cellules ayant des duplications de gènes et leurs utilisations
EP4343004A3 (fr) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Biomarqueurs germinaux de réponse clinique et de bénéfice d'une thérapie par inhibiteur de point de contrôle immunitaire
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (fr) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
CA3227875A1 (fr) 2021-08-02 2023-02-09 Pfizer Inc. Vecteurs d'expression ameliores et leurs utilisations
EP4408982A1 (fr) 2021-09-27 2024-08-07 SOTIO Biotech Inc. Polypeptides récepteurs chimériques en combinaison avec des molécules de métabolisme trans qui réorientent des métabolites de glucose hors de la voie de glycolyse et leurs utilisations thérapeutiques
IL312540A (en) 2021-11-16 2024-07-01 Sotio Biotech Inc Treatment of patients with myxoid/round cell liposarcoma
WO2023097119A2 (fr) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
AU2023213817A1 (en) 2022-01-31 2024-08-01 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (fr) 2022-02-02 2023-08-10 Pfizer Inc. Prototrophie cystéinique
WO2023158732A1 (fr) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (fr) 2022-08-19 2024-02-22 Sotio Biotech Inc. Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques
WO2024040208A1 (fr) 2022-08-19 2024-02-22 Sotio Biotech Inc. Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019798A1 (fr) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vecteurs contenant des sequences d'encapsidation du vih, vecteurs du vih a capside defectueux, et leur utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019798A1 (fr) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vecteurs contenant des sequences d'encapsidation du vih, vecteurs du vih a capside defectueux, et leur utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9325698A1 *
VIROLOGY, vol. 152, no. 1, 1986, ORLANDO US, pages 268-271, XP002021491 BANAPOUR, B. ET AL.: "The Acquired Immunodeficiency Syndrome associated retrovirus is not sensitive to lysis or inactivation by human serum " *

Also Published As

Publication number Publication date
CA2137361A1 (fr) 1993-12-23
WO1993025698A1 (fr) 1993-12-23
JPH09507741A (ja) 1997-08-12
EP0644946A4 (fr) 1997-03-12

Similar Documents

Publication Publication Date Title
WO1993025698A1 (fr) Particules vecteurs resistantes a l'inactivation par le serum humain
WO1993025698A9 (fr) Particules vecteurs resistantes a l'inactivation par le serum humain
EP0746625B1 (fr) Particules vectorielles pouvant etre ciblees
US5449614A (en) Recombinant retroviruses with amphotropic and ecotropic host ranges
US5925345A (en) Vectors including foreign genes and negative selective markers
Shimada et al. Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector.
Buchholz et al. In vivo selection of protease cleavage sites from retrovirus display libraries
Robbins et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells
CA1315719C (fr) Lignees cellulaires utilisees pour l'encapsidation de retrovirus et modes d'utilisation
US5672510A (en) Retroviral vectors
Kim et al. Construction of retroviral vectors with improved safety, gene expression, and versatility
US5747323A (en) Retroviral vectors comprising a VL30-derived psi region
JP2003530064A (ja) 遺伝子治療用のコートタンパク質改変バキュロウイルス−ベクター
US5554524A (en) More complex type retroviruses having mixed type LTR, and uses thereof
US5576201A (en) Retroviral vector particles for transducing non-proliferating cells
JP3908274B2 (ja) 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
US5580766A (en) Retroviral vector particles for transducing non-proliferating cells
US5736360A (en) Endothelial cell tropic compositions and methods of making and using the same
US5837503A (en) Vector containing viral gene transcribed by RNA polymerase III and methods for use
Wolff et al. Tissue tropism of a leukemogenic murine retrovirus is determined by sequences outside of the long terminal repeats.
EP0511311A1 (fr) Nouveaux vecteurs retroviraux
US6762031B2 (en) Targeting viral vectors to specific cells
Antoine et al. Envelope and long terminal repeat sequences of an infectious murine leukemia virus from a human SCLC cell line: implications for gene transfer
Baum et al. Contribution of the retroviral leader to gene transfer and expression in packaging cells and myeloid stem and progenitor cells
EP1061129A1 (fr) Rétrovirus infectieux de lignée cellulaire de chien leucémique ayant une grande homologie avec le virus de la leucémie murine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/86

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971201